688089 Cabio Biotech(Wuhan)
- 15.58
- +0.01+0.06%
Cabio Biotech(Wuhan) News
Jia Biyou (688089.SH): Major customers have proposed clear plans to replace DHA in seaweed oil with DHA in fish oil, and the company is also actively participating
Gelonghui, May 16 | Jia Biyou (688089.SH) said on the investor interactive platform that the company's product pricing adopts the overall strategy of “one household, one policy, one product, one case”, and that there are differences in pricing for customers in different regions and application fields. In recent years, due to the influence of factors such as marine pollution and increased global ESG requirements, the global trend of replacing DHA in fish oil has accelerated. In the field of infant formula, major customers have proposed clear plans to replace DHA in seaweed oil with DHA in fish oil, and the company is also actively participating.
Jia Biyou (688089.SH): The company is based on synthetic biology
Gelonghui, May 16, 丨 Jia Biyou (688089.SH) said on the investor interactive platform that the company is based on synthetic biology. Currently, its main products include polyunsaturated fatty acid ARA, algae oil DHA, terpenoid substances beta-carotene, astaxanthin, etc., and the sugar substances SA and hMOS, etc., which are widely used in infant formula, health food, animal nutrition, personal care and beauty. It is also continuously expanding into biomedicine, biomaterials, biological agriculture, etc. based on the underlying technical characteristics of synthetic biology. field.
Express News | Jia Biyou: The company has opened up the entire synthetic biology technology chain to develop a series of HMO products
Jia Biyou (688089.SH) received a warning letter from the Hubei Securities Regulatory Bureau
Jia Biyou (688089.SH) announced that on May 15, 2024, the company received the “Decision of the Hubei Securities Regulatory Bureau on Issuing Warning Letter Measures against Jiabiyou Biotechnology (Wuhan) Co., Ltd., Yi Dewei, Yi Huarong, and Wang Huabiao” ([2024] No. 24) (“Warning Letter”) issued by the Hubei Regulatory Bureau of the China Securities Regulatory Commission.
The synthetic biology concept opened high and went low. Jiabiyou fell more than 5%, Tebao Biotech and Shengda Biotech fell by more than 4%, and Boen Group and Hanyu Pharmaceutical collectively fell.
The synthetic biology concept opened high and went low. Jiabiyou fell more than 5%, Tebao Biotech and Shengda Biotech fell by more than 4%, and Boen Group and Hanyu Pharmaceutical collectively fell.
Express News | Jia Biyou: The company's daily business situation is normal and there have been no major changes recently
The food processing sector fluctuated and boosted. Jiabiyou surged 13%, Qiaqia Foods rose more than 6%, and Bowling Bao, Sweet Foods, Jinzai Foods, and Hairong Technology followed suit.
The food processing sector fluctuated and boosted. Jiabiyou surged 13%, Qiaqia Foods rose more than 6%, and Bowling Bao, Sweet Foods, Jinzai Foods, and Hairong Technology followed suit.
The synthetic biology concept continued to be strong. Blue Biotech had 3 consecutive sales, Channing Biotech surged 15%, and Langkun Environmental, Fuxiang Pharmaceutical, and Jiabiyou had advanced gains.
The synthetic biology concept continued to be strong. Blue Biotech had 3 consecutive sales, Channing Biotech surged 15%, and Langkun Environmental, Fuxiang Pharmaceutical, and Jiabiyou had advanced gains.
Jia Biyou (688089): Gross margin improved year-on-year in Q1 beyond expectations
Guide to this report: The 24Q1 company's performance exceeded expectations, mainly due to a significant recovery in revenue from overseas customers and a recovery in gross margin. Subsequent major overseas customers and new HMO product expansion are expected to help medium- to long-term growth. Investment Highlights: Investment Suggestions to Consider
Jia Biyou (688089): 23-year results are in line with market expectations, 1Q24 profit margins have recovered
The 23-year results were in line with market expectations, and the 1Q24 performance slightly exceeded market expectations. The company announced 2023&1Q24 results: the company's revenue in 2023 was 404 million yuan, +2.4% year-on-year, and net profit to mother was 91 million yuan
Guoyuan Securities released a research report on April 27 stating that it gave Jiabiyou (688089.SH) a purchase rating. The main reasons for the rating include: 1) revenue +33% in 2024Q1; 2) the implementation of the new national standard increased domesti
Guoyuan Securities released a research report on April 27 stating that it gave Jiabiyou (688089.SH) a purchase rating. The main reasons for the rating include: 1) revenue +33% in 2024Q1; 2) the implementation of the new national standard increased domestic demand, and overseas revenue resumed growth in 2023H2; 3) steady gross margin and a recovery in net income to mother; 4) demand for ARA & DHA cornerstone products is expected to grow under both domestic and foreign opportunities. (Mainichi Keizai Shimbun)
Jia Biyou (688089): A bright start to Q1, looking forward to more throughout the year
Event: Jiabiyou announced its 2023 annual report and 2024 quarterly report. In 2023, the company achieved operating income of 444 million yuan, +2.39% year on year; net profit to mother was 91.37 million yuan, +41.95 percent year on year
Jia Biyou (688089): Accelerating the expansion of overseas markets, new HMOS products are expected to launch
Core idea The implementation of the new national standard in the first three quarters of 2023 has led to a significant increase in revenue from ARA and DHA products, and the company's revenue increased throughout the year. Factors such as the declining population and the fact that leading downstream companies are removing inventory to reduce channel pressure
Jiabiyou (688089.SH) announced its 2023 annual results, with net profit of 91.3742 million yuan, an increase of 41.95% over the previous year
Jia Biyou (688089.SH) released its 2023 annual report. The company's revenue was 444 million yuan, up 2.39% year on year; net profit attributable to shareholders of listed companies was 91.3742 million yuan, up 41.95% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 62.445 million yuan, up 103.17% year on year; basic earnings per share were 0.54 yuan/share. It is proposed to distribute a cash dividend of 2.00 yuan (before tax) for every 10 shares to all shareholders.
Jia Biyou (688089): Fundamentals are stabilizing, the trend is improving, synthetic biotechnology and new HMO products are ready to go
Incident: The company released its 2023 performance report. After preliminary accounting, the company achieved total revenue of 445 million yuan in '23, an increase of 2.78% over the previous year, and net profit to mother of 92 million yuan, an increase of 42.17% over the previous year. 1. Net
Cabio Biotech (Wuhan) Co., Ltd. (SHSE:688089) Soars 27% But It's A Story Of Risk Vs Reward
Those holding Cabio Biotech (Wuhan) Co., Ltd. (SHSE:688089) shares would be relieved that the share price has rebounded 27% in the last thirty days, but it needs to keep going to repair the recent dam
Express News | Jia Biyou: Obtained the invention patent “Application of sialic acid in weight loss and weight loss inhibition”
Jia Biyou (688089.SH): The trend of replacing fish oil with algae oil has gradually emerged in recent years
Gelonghui, March 19 | Jia Biyou (688089.SH) said on the investor interactive platform that the company currently produces algae oil DHA independently. After the fund-raising project is put into operation, the DHA oil production capacity can be increased from 150 tons to 600 tons. The powder production capacity is shared between ARA and DHA, and the total powder production capacity has also increased from 1,200 tons to 2,700 tons. Fish oil DHA and algae oil DHA each have obvious advantages in different application scenarios. Because seaweed oil DHA is produced in sealed fermenters through biological fermentation technology, the production process is clean, controllable and traceable, and is more environmentally friendly and safe, plus algae oil DH
Jia Biyou (688089): Fourth quarter revenue pressure actively lays out overseas markets
Core view The implementation of the new national standard led to an increase in the company's revenue throughout the year, achieving revenue of 445 million yuan, an increase of 2.78% over the previous year. Due to the approach of the new national standard in the fourth quarter of 2022, downstream demand for the company's products increased markedly. Under a high base, the company
Express News | Jia Biyou: Net profit of 91.56 million yuan in 2023 increased 42.17% year on year
Analysis
Price Target
No Data
